Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial
Strauss, Kevin A ; Farrar, Michelle A ; Muntoni, Francesco ; Saito, Kayoko ; Mendell, Jerry R ; Servais, Laurent ; McMillan, Hugh J ; Finkel, Richard S ; Swoboda, Kathryn J ; Kwon, Jennifer M ... show 10 more
Citations
Authors
Farrar, Michelle A
Muntoni, Francesco
Saito, Kayoko
Mendell, Jerry R
Servais, Laurent
McMillan, Hugh J
Finkel, Richard S
Swoboda, Kathryn J
Kwon, Jennifer M
Zaidman, Craig M
Chiriboga, Claudia A
Iannaccone, Susan T
Krueger, Jena M
Parsons, Julie A
Shieh, Perry B
Kavanagh, Sarah
Wigderson, Melissa
Tauscher-Wisniewski, Sitra
McGill, Bryan E
Macek, Thomas A
Student Authors
Faculty Advisor
Academic Program
UMass Chan Affiliations
Document Type
Publication Date
Keywords
Subject Area
Embargo Expiration Date
Link to Full Text
Abstract
Most children with biallelic SMN1 deletions and three SMN2 copies develop spinal muscular atrophy (SMA) type 2. SPR1NT ( NCT03505099 ), a Phase III, multicenter, single-arm trial, investigated the efficacy and safety of onasemnogene abeparvovec for presymptomatic children with biallelic SMN1 mutations treated within six postnatal weeks. Of 15 children with three SMN2 copies treated before symptom onset, all stood independently before 24 months (P < 0.0001; 14 within normal developmental window), and 14 walked independently (P < 0.0001; 11 within normal developmental window). All survived without permanent ventilation at 14 months; ten (67%) maintained body weight (≥3rd WHO percentile) without feeding support through 24 months; and none required nutritional or respiratory support. No serious adverse events were considered treatment-related by the investigator. Onasemnogene abeparvovec was effective and well-tolerated for presymptomatic infants at risk of SMA type 2, underscoring the urgency of early identification and intervention.
Source
Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, McMillan HJ, Finkel RS, Swoboda KJ, Kwon JM, Zaidman CM, Chiriboga CA, Iannaccone ST, Krueger JM, Parsons JA, Shieh PB, Kavanagh S, Wigderson M, Tauscher-Wisniewski S, McGill BE, Macek TA. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. Nat Med. 2022 Jul;28(7):1390-1397. doi: 10.1038/s41591-022-01867-3. Epub 2022 Jun 17. PMID: 35715567; PMCID: PMC9205287.